Form 4: Apogee Therapeutics Director Lisa Bollinger Reports Stock Option Grant

Director Lisa Bollinger reports receiving a stock option grant for 8,112 shares of Apogee Therapeutics common stock.

Summary

• Lisa Bollinger, a director of Apogee Therapeutics, Inc. (APGE), filed a Form 4 on June 7, 2024, reporting a transaction that occurred on June 5, 2024.
• The transaction involved the grant of a stock option to purchase 8,112 shares of Apogee Therapeutics common stock at an exercise price of $43.85.
• The stock option vests on the one-year anniversary of the grant date, contingent upon Lisa Bollinger's continued service to the Issuer.

Sentiment

Score: 6

Explanation: The document is a routine regulatory filing related to stock option grants, which is generally neutral. The sentiment is slightly positive as it indicates alignment of director interests with shareholders.

Positives

• The grant of stock options to directors can align their interests with those of shareholders, incentivizing them to work towards the company's success.

Industry Context

Stock options are a common form of compensation for directors and executives in publicly traded companies, particularly in the biotechnology and pharmaceutical industries, to incentivize performance and align interests with shareholders.

Stakeholder Impact

• The stock option grant could potentially impact shareholders by aligning the director's interests with the company's long-term success.

Key Dates